In-Depth Insights into the Non-Alcoholic Steatohepatitis Biomarkers Market: Growth, Trends, and Opportunities for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What Are the Projected Expansion Rates of the Non-Alcoholic Steatohepatitis Biomarkers Market for the Next Decade?
In recent times, there has been exponential growth observed in the non-alcoholic steatohepatitis biomarkers market. The market, which was worth $1.36 billion in 2024, is expected to rise to $1.7 billion in 2025, growing at a compound annual growth rate (CAGR) of 24.8%. Factors such as diabetes and metabolic syndrome, increased awareness and screening programs, the limitations of liver biopsies, regulatory backing, a shift towards personalized medicine, and clinical trials in non-alcoholic steatohepatitis (NASH), have all contributed to the growth during the historic period.
It is projected that the non-alcoholic steatohepatitis biomarkers market will experience massive expansion in the near future. The market is poised to hit a valuation of $3.86 billion in 2029, rocketing at a compound annual growth rate (CAGR) of 22.8%. This impressive growth during the projection period can be linked to the development of new treatments, the broadening of precision medicine methodologies, initiatives for patient advocacy, the amalgamation of multi-omics data and better patient involvement. The forecast period will see critical trends such as the use of telemedicine and remote monitoring, inventive diagnostic platforms, international cooperation in research, advances in biomarker discovery technology, the incorporation of artificial intelligence (AI), and the adoption of imaging biomarkers.
What Combination of Drivers Is Leading to Accelerated Growth in the non-alcoholic steatohepatitis biomarkers Market?
The rise in liver cancer cases is anticipated to stimulate expansion in the non-alcoholic steatohepatitis biomarkers market. Liver cancer involves the growth of malignant tumors in the liver and can originate from the liver (primary liver cancer), or metastasize to the liver from other body parts (secondary or metastatic liver cancer). Biomarkers for non-alcoholic steatohepatitis (NASH) are employed in initial detection, monitoring of disease progression, and assessing treatment responses in liver cancer. They deliver prognostic data and can minimize the requirement for invasive procedures. For example, the World Cancer Research Fund, a not-for-profit organization based in the UK, reported around 866,136 fresh liver cancer cases globally in 2022, making liver cancer the 6th most common cancer worldwide. Therefore, the increasing prevalence of liver cancer is advancing the growth of the non-alcoholic steatohepatitis biomarkers market.
Explore Comprehensive Insights Into The Global Non-Alcoholic Steatohepatitis Biomarkers Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp
Which Companies Are Redefining the Future of the Non-Alcoholic Steatohepatitis Biomarkers Market?
Major companies operating in the non-alcoholic steatohepatitis biomarkers market include:
• Genfit SA_x000D_
• Prometheus Laboratories Inc._x000D_
• Siemens Medical Solutions USA Inc._x000D_
• BioPredictive_x000D_
• Quest Diagnostics_x000D_
What Trends Are Poised to Drive the Future Success of the Non-Alcoholic Steatohepatitis Biomarkers Market?
The surge in technological advancements in the field of non-alcoholic steatohepatitis biomarkers is becoming a notable trend, allowing market-leading companies to offer innovative solutions and secure their market standing. For example, in October 2022, an agreement was established between GENFIT, a biopharmaceutical firm based in France, and LabCorp, a life sciences company in the US. The five-year exclusive licensing deal involves the utilization of GENFIT’s NIS4 technology which is designed to recognize NASH-at-risk patients. This groundbreaking, multi-biomarker centric algorithm specifically aims to pinpoint patients suffering from non-alcoholic steatohepatitis (NASH) as well as significant to advanced fibrosis (F > 2), often referred to as at-risk NASH. As per the terms of the agreement, LabCorp is tasked with the creation and commercial marketing of a blood-based molecular diagnostic exam that employs the NIS4 technology, broadening its availability to healthcare professionals in the United States and Canada.
Secure Your Global Non-Alcoholic Steatohepatitis Biomarkers Market Report Now for Fast and Efficient Delivery!
Which Segments Play a Crucial Role in the Expansion of the Non-Alcoholic Steatohepatitis Biomarkers Market?
The non-alcoholic steatohepatitis biomarkers market covered in this report is segmented –
1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses
Subsegments:
1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index
2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers
What Are the Leading Regions in the Non-Alcoholic Steatohepatitis Biomarkers Market Expansion?
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
How Is the Non-Alcoholic Steatohepatitis Biomarkers Market Classified and Defined in Market Analysis?
Non-alcoholic steatohepatitis (NASH) is a type of liver inflammation and damage caused by a build-up of fat in the liver. NASH biomarkers are used as diagnostic tools to assess the severity of non-alcoholic steatohepatitis and to assess liver damage. This damages the liver cells and inflames the liver, which can result in cirrhosis (liver scarring) and liver failure. Biomarkers refer to a particular quality that can be tested to reveal pathogenic processes, healthy biological processes, or reactions to exposure or treatment.
Browse Through More Similar Reports By The Business Research Company:
Alcoholic – Beverages Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/alcoholic-beverages-global-market-report
Food And Beverages E-Commerce Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/food-and-beverages-ecommerce-global-market-report
Prosthetic Heart Valve Devices And Equipment Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
